Compare Endeavour Silver Corp (EXK) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Smith & Nephew plc — how do they compare? Endeavour Silver Corp trades at $8.74 (market cap $2.54B), while Smith & Nephew plc trades at $27.28 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 4.4× Endeavour Silver Corp's market cap, and Smith & Nephew plc pays a 2.95% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Endeavour Silver Corp for 25 Days and Smith & Nephew plc for 120 Days on average.
| EXK | SNN | |
|---|---|---|
Market Cap | $2.54B | $11.10B |
Volume | 7,077,330 | 1,051,703 |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $37.17 |
52-Week Low | $7.07 | $26.42 |
Typical Hold Time | 25 Days | 120 Days |
Enterprise Value | $2.54B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Endeavour Silver (EXK) trades at $8.77, up 5.41% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. The company reported strong Q1 2026 earnings beat but missed Q2 expectations, with revenue projected to grow from $468M in 2025 to $737M in 2026. Recent developments include operational progress at Terronera mine and resolution of blockade issues, while maintaining a 78.57% analyst buy rating.
EXK presents growth potential through mine expansions and favorable silver prices, but faces execution risks from operational disruptions and negative 2025 net income. The stock's high P/E ratio of 42.85 suggests premium valuation, requiring careful monitoring of production targets and cost management for sustained profitability improvement.
SNN trades at $26.89, near its 52-week low, with a bearish technical signal. Revenue and net income have grown steadily, reaching $6.16B and $625M in 2025, respectively, with improving margins. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. However, cash flow volatility and mixed analyst sentiment pose challenges.
The stock presents a value opportunity with reasonable valuation ratios (P/E 18.34, P/S 1.85), but risks include competitive pressures and recent CFO departure. Analyst consensus is cautious, with 65% hold ratings. Upside depends on execution of growth initiatives amid market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
